Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2247 ARTÍCULOS , VIENDO DEL 451 AL 465

Small World derived index to distinguish Alzheimer's type dementia and healthy subjects

Vecchio F, Miraglia F, Pappalettera C, Nucci L, Cacciotti A, Rossini PM.

Age Ageing. 2024 Jun 1;53(6):afae121. doi: 10.1093/ageing/afae121.

Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development

Cummings JL, Osse AML, Kinney JW, Cammann D, Chen J.

CNS Drugs. 2024 Aug;38(8):613-624. doi: 10.1007/s40263-024-01103-1. Epub 2024 Jun 27.

Phytoactive drugs used in the treatment of Alzheimer's disease and dementia

Soni AG, Verma A, Joshi R, Shah K, Soni D, Kaur CD, Saraf S, Chauhan NS.

Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8633-8649. doi: 10.1007/s00210-024-03243-z. Epub 2024 Jun 28.

BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives

Coimbra JRM, Resende R, Custódio JBA, Salvador JAR, Santos AE.

J Alzheimers Dis. 2024;101(s1):S53-S78. doi: 10.3233/JAD-240146.

Beyond Amyloid-β: Reevaluating Its Physiological Role to Find Safe Therapies Against Alzheimer's Disease

Puzzo D.

J Alzheimers Dis. 2024;100(3):783-786. doi: 10.3233/JAD-240406.

Effects of ketogenic diet on cognitive function of patients with Alzheimer's disease: a systematic review and meta-analysis

Rong L, Peng Y, Shen Q, Chen K, Fang B, Li W.

J Nutr Health Aging. 2024 Aug;28(8):100306. doi: 10.1016/j.jnha.2024.100306. Epub 2024 Jun 28.

[Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease.]

Ilina AR, Popovich IG, Ryzhak GA, Khavinson VK.

Adv Gerontol. 2024;37(1-2):10-20.

Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives

Suzuki N, Hatta T, Ito M, Kusakabe KI.

Chem Pharm Bull (Tokyo). 2024;72(7):602-609. doi: 10.1248/cpb.c24-00069.

Neuroimmune Dysfunction in Alzheimer's Disease and Other Forms of Dementia

Yamane T, Yoshioka T, Shimo Y.

Chem Pharm Bull (Tokyo). 2024;72(7):618-629. doi: 10.1248/cpb.c23-00464.

Epigenetic Inhibitors as Alzheimer's Disease Therapeutic Agents

Yamashita Y, Itoh Y, Takada Y, Suzuki T.

Chem Pharm Bull (Tokyo). 2024;72(7):630-637. doi: 10.1248/cpb.c23-00027.

Comparing Unmet Service Needs Between Rural and Urban Family Caregivers of People Living With Alzheimer's Disease and Related Dementias: A Multisite Study

Miyawaki CE, McClellan A, Russell D, Bouldin ED.

Gerontologist. 2024 Sep 1;64(9):gnae083. doi: 10.1093/geront/gnae083.

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

Zhao J, Wei M, Guo M, Wang M, Niu H, Xu T, Zhou Y.

CNS Neurosci Ther. 2024 Jul;30(7):e14818. doi: 10.1111/cns.14818.

Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review

Lee JY, Wong CY, Koh RY, Lim CL, Kok YY, Chye SM.

Yale J Biol Med. 2024 Jun 28;97(2):205-224. doi: 10.59249/JNKB9714. eCollection 2024 Jun.

Delineation of the role of G6PD in Alzheimer's disease and potential enhancement through microfluidic and nanoparticle approaches

Sharallah OA, Poddar NK, Alwadan OA.

Ageing Res Rev. 2024 Aug;99:102394. doi: 10.1016/j.arr.2024.102394. Epub 2024 Jun 29.

Revisiting the focal role of endostatin and environmental factors in Alzheimer's disease

Behl T, Dahim MA, Aleya L.

Environ Sci Pollut Res Int. 2024 Jul;31(32):44511-44517. doi: 10.1007/s11356-024-34113-z. Epub 2024 Jun 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias